Citigroup
CRSP icon

Citigroup’s CRISPR Therapeutics CRSP Stock Holding History

Citigroup’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.32M Buy
60,000
+9,000
+18% +$486K ﹤0.01% 2426
2026
Q2 		$2.78M Buy
+51,000
New +$2.69M ﹤0.01% 2663
2025
Q3 		– Sell
-33,200
Closed -$1.61M – 6127
2025
Q2 		$1.61M Buy
+33,200
New +$1.28M ﹤0.01% 2828
2025
Q1 		– Sell
-20,400
Closed -$803K – 5660
2024
Q4 		$803K Buy
+20,400
New +$963K ﹤0.01% 3528
2023
Q2 		– Sell
-30,000
Closed -$1.36M – 5587
2023
Q1 		$1.36M Buy
+30,000
New +$1.46M ﹤0.01% 2317
2022
Q4 		– Sell
-20,000
Closed -$1.31M – 5800
2022
Q3 		$1.31M Buy
+20,000
New +$1.45M ﹤0.01% 2495
2021
Q1 		– Sell
-86,100
Closed -$13.2M – 6440
2020
Q4 		$13.2M Buy
86,100
+29,300
+52% +$3.46M 0.01% 1332
2020
Q3 		$4.75M Sell
56,800
-47,300
-45% -$4.2M ﹤0.01% 1920
2020
Q2 		$7.65M Sell
104,100
-21,800
-17% -$1.27M 0.01% 1524
2020
Q1 		$5.34M Buy
125,900
+52,000
+70% +$2.68M ﹤0.01% 1614
2019
Q4 		$4.5M Buy
73,900
+39,400
+114% +$2.15M ﹤0.01% 2119
2019
Q3 		$1.41M Sell
34,500
-16,200
-32% -$774K ﹤0.01% 3256
2019
Q2 		$2.39M Buy
50,700
+27,200
+116% +$1.09M ﹤0.01% 2654
2019
Q1 		$839K Buy
23,500
+14,400
+158% +$498K ﹤0.01% 3592
2018
Q4 		$260K Buy
9,100
+4,400
+94% +$153K ﹤0.01% 4763
2018
Q3 		$208K Buy
+4,700
New +$246K ﹤0.01% 5211

Other funds holding CRSP

State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $824B AUM 37.44% 1-Year Est. Return
GSK plc
GSK plc London $497M AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $483B AUM 27.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Citigroup's CRSP Position: Q3 2026 in Review

Citigroup reduced its CRISPR Therapeutics (CRSP) stake by 27% in Q3 2026, selling an estimated $1.66M and leaving 83,477 shares worth $4.62M. The position accounts for ﹤0.01% of the portfolio, ranked #2174.

Citigroup first reported a position in CRSP in Q1 2017 and has held it in 38 quarters since. The position peaked at $8.64M in Q1 2023. 340 funds tracked by Wall St. Rank hold CRSP as of Q3 2026.

  • Citigroup held 83,477 shares of CRISPR Therapeutics worth $4.62M as of Q3 2026.
  • Citigroup sold 30,839 CRISPR Therapeutics shares in Q3 2026, an estimated $1.66M.
  • CRISPR Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #2174 holding.
  • Citigroup first reported a position in CRISPR Therapeutics in Q1 2017 and has held it in 38 quarters since.
  • Citigroup's CRISPR Therapeutics position peaked at $8.64M in Q1 2023.
  • 340 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.